Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Apellis (Nasdaq: APLS) will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live webcast will be posted on the company’s Events and Presentations investor page and a replay will be available for approximately 30 days following the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
APLS fell 2.28% while key biotech peers like SRRK, IMVT, KYMR, and TLX in sector context showed gains between 1.31% and 3.08%, with PTGX down 0.6%. Momentum peers were mixed, with MLTX up 6.55% and TLX down 8.97%, suggesting stock-specific dynamics rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Scientific meeting data | Positive | +1.9% | Multiple Macula Society oral presentations including five-year GALE extension results. |
| Feb 10 | Earnings call scheduling | Neutral | -1.1% | Announcement of Q4 and full-year 2025 earnings call and webcast logistics. |
| Jan 12 | Commercial update | Positive | -15.0% | Preliminary 2025 revenues, strong SYFOVRE uptake, EMPAVELI growth, and pipeline plans. |
| Jan 05 | Conference presentation | Neutral | -3.8% | Planned J.P. Morgan Healthcare Conference presentation and webcast availability. |
| Dec 03 | Phase 3 trial results | Positive | +2.9% | Positive Phase 3 VALIANT outcomes for EMPAVELI in C3G and IC-MPGN published in NEJM. |
Positive clinical and scientific updates have often coincided with gains, while strong commercial or strategic updates have previously seen at least one notable negative reaction.
Over the last few months, Apellis has combined scientific visibility, commercial updates, and pipeline progress. On Dec 3, positive Phase 3 VALIANT results and prior July 28, 2025 FDA approval saw shares rise 2.86%. A J.P. Morgan update on Jan 12 reported strong 2025 revenue and cash metrics yet shares fell 15.02%. Conference-related announcements on Jan 5 and Feb 10 produced modest declines, while Macula Society presentation news on Feb 19 aligned with a 1.89% gain. Today’s conference appearance fits this cadence of frequent investor-facing events.
Market Pulse Summary
This announcement highlights another investor-facing appearance as Apellis engages at the TD Cowen conference on March 2, 2026 at 9:50 a.m. ET, with a webcast replay available for 30 days. Set against recent clinical milestones, commercial updates, and frequent conference participation, it extends the company’s communication cadence. Investors monitoring the story may focus on how messaging at this event builds on prior Phase 3 data, market-share trends, and capital markets disclosures reported in recent months.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
FAQ
When will Apellis (APLS) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the Apellis (APLS) TD Cowen webcast on March 2, 2026?
Will a replay of the Apellis (APLS) TD Cowen presentation be available and for how long?
What format will Apellis (APLS) use for its March 2, 2026 TD Cowen presentation?
Where on the Apellis (APLS) website will the TD Cowen webcast be posted?
